Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
42 participants
INTERVENTIONAL
2014-03-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention
NCT02748330
PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor
NCT02698618
Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)
NCT02457130
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
NCT01643031
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
NCT01823510
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ticagrelor group
Ticagrelor 90 mg twice daily + standard medical therapy
Ticagrelor
Ticagrelor 90 mg twice daily
Standard medical therapy
Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Clopidogrel group
Clopidogrel 150 mg once daily + standard medical therapy
Clopidogrel
Clopidogrel 150 mg once daily
Standard medical therapy
Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ticagrelor
Ticagrelor 90 mg twice daily
Clopidogrel
Clopidogrel 150 mg once daily
Standard medical therapy
Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stable coronary disease
* coronary revascularization with PCI at least 1 month prior to recruitment
Exclusion Criteria
* platelet count \<70x109/l
* active bleeding or bleeding diathesis
* history of intracranial bleeding
* gastrointestinal bleeding \<6 months
* cerebrovascular accident \<3 months
* history of malignancy
* concomitant need for oral anticoagulant therapy
* severe liver disease or chronic renal failure (glomerular filtration rate \<30 ml/min /1.73m2)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Campus Bio-Medico University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Germano Di Sciascio
Prof. Germano Di Sciascio
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLOTILDIA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.